AMBU OBTAINS FDA CLEARANCE FOR WORLD’S FIRST SINGLE-USE THERAPEUTIC GASTROSCOPE
Ambu’s aScope™ Gastro Large, with its 4.2 mm working channel and endoscope handle made with bioplastics, expands the company’s single-use portfolio for upper gastroenterology (GI) procedures. The expanded portfolio allows physicians to address an extended range of needs across the ICU, OR and endoscopy suite.
Today, Ambu announces 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) of its therapeutic gastroscope solution, Ambu® aScope™ Gastro Large and Ambu® aBox™ 2.
The clearance signifies an extended solution offering for surgeons and gastroenterologists performing upper GI procedures. With the expanded endoscope portfolio – consisting of the aScope™ Gastro and the aScope™ Gastro Large – physicians are now equipped to address a wider range of needs in various hospital settings, covering the operating room (OR), the intensive care unit (ICU) and the endoscopy unit. Globally, the aScope™ Gastro Large targets 1.5 million annual procedures, while the aScope™ Gastro is expected to meet needs within a market of 2 million annual procedures.
The aScope™ Gastro Large is, with its 4.2 mm working channel and powerful suction performance, designed to addresses acute therapeutic procedures in the ICU, such as bleed management and food impaction, as well as direct endoscopic necrosectomy and stenting in the endoscopy unit. Compared to the industry-leading 3.7 mm therapeutic gastroscopes on the market, the working channel of the aScope™ Gastro Large delivers significantly higher suction performance1, both with and without tools, thereby constituting a valuable tool for managing acute upper GI bleeding. Complimentarily, the aScope™ Gastro targets procedures outside of the endoscopy unit, such as surgical gastroscopies in the OR and bedside procedures in the ICU.
"I look forward to utilizing the innovative aScope Gastro Large single-use gastroscope technology for interventions that require superior suction. The gastroscope’s 4.2 mm working channel will facilitate clot and blood clearance and removal of necrotic debris during direct endoscopic necrosectomy. Operationally, the immediate availability of a disposable scope to be utilized in urgent cases in various locations without the need for reprocessing will improve downstream efficiencies and minimize barriers to providing urgent endoscopic care to our patients."
MARK A. GROMSKI, MD, FASGE2
Director, Advanced Endoscopy, Indiana University School of Medicine
TWO WORLD’S FIRSTS: 4.2 MM WORKING CHANNEL AND HANDLE MADE WITH BIOPLASTICS
The aScope™ Gastro Large represents two world firsts within the endoscopy market. Not only is it the first single-use therapeutic gastroscope with a 4.2 mm working channel; it is also the world’s first endoscope made with bioplastics.
The bioplastic materials in the gastroscope handle are derived from a mix of fossil-based and second-generation feedstock, e.g., recycled food waste, ensuring that it has a lower carbon footprint. The large gastroscope is the first of Ambu’s fleet of endoscopes to be manufactured with bioplastics and thus represents an important step forward in the company’s commitment to integrating bioplastics in all future endoscope handles by the end of 2024.
Ambu announced European regulatory clearance (CE mark) of the aScope™ Gastro Large in September 2023 and now extends its commercialisation to North America. CEO Britt Meelby Jensen is excited about the FDA clearance and to bringing an expanded and advanced gastroscopy portfolio to customers in Ambu’s biggest market:
"Our therapeutic gastroscope solution is a vital step forward in our gastroenterology journey. Not only does it expand and strengthen our gastroscope portfolio, empowering U.S. physicians with two complimentary high-performance solutions for upper GI procedures targeting diverse clinical needs; it also marks an important way forward for hospitals and GI professionals wishing to alleviate the strain of reprocessing, optimise workflow and bring faster care to patients."
BRITT MEELBY JENSEN
Chief Executive Officer, Ambu
-----------------------------------------------------------------------------
1 Suction data based on bench top test with 10 Fr bipolar probe.
2 Dr. Gromski is a paid consultant of Ambu A/S. He has not been compensated for his quote in this press release.
Not all Ambu products are available for commercial sale in all countries.
Keywords
Contacts
Tine Bjørn SchmidtHead of Corporate Communications
Tel:+45 2264 0697tisc@ambu.comAnders HjortHead of Investor Relations
Tel:+45 2892 8881anhj@ambu.comDocuments
ABOUT AMBU
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
Subscribe to releases from Ambu A/S
Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Ambu A/S
AMBU LAUNCHES HD CYSTOSCOPY SOLUTION IN THE U.S.17.10.2024 16:46:40 CEST | Press release
Following the FDA clearance for the Ambu® aScope™ 5 Cysto HD solution, Ambu introduces its HD cystoscope to urologists in the USA, expanding the urology offering and meeting advanced needs for cystoscopy procedures requiring superior image quality.
AMBU OBTAINS CE MARK FOR NEW GENERATION DUODENOSCOPY SOLUTION8.8.2024 13:00:00 CEST | Press release
Having obtained both CE mark and FDA clearance, Ambu continues its controlled market release phase, focused on evaluation in key hospitals in the USA and Europe.
AMBU OBTAINS FDA CLEARANCE FOR NEW URETEROSCOPY ENDOSCOPY SOLUTION26.6.2024 14:00:00 CEST | Press release
The new clearance marks Ambu’s rapidly growing presence in urology, advancing the company’s urology portfolio in the U.S. market.
AMBU ANNOUNCES NEW CHIEF OPERATIONS OFFICER10.6.2024 11:00:00 CEST | Press release
Henrik Birk steps down from his position as Chief Operations Officer at Ambu. Former Novozymes COO, Graziela Malucelli, takes on the position, effective immediately.
AMBU OBTAINS FDA CLEARANCE FOR NEW GENERATION DUODENOSCOPY SOLUTION19.4.2024 09:00:00 CEST | Press release
To meet the unique needs of gastroenterologists performing ERCP procedures, Ambu’s new generation aScope Duodeno 2 solution constitutes a step change from previous generations, driven by valuable collaboration with healthcare professionals.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom